The results of this research demonstrated that autologous nanobody-derived fratricide-resistant CD7 CAR-T cell therapy exhibits sustained effectiveness in patients with relapsed/refractory T-ALL/LBL, without inducing severe cytokine release syndrome, neurologic toxicity, or T-cell aplasia [177]. Here, CD7 is linked to acute lymphoblastic leukemia.